HEIDELBERG, Germany, Oct. 6, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that the Company's abstract has been chosen for a poster presentation at the 30th annual Society for Immunotherapy of Cancer (SITC) conference, being held November 4-8 in National Harbor, Maryland. This will be the first publication of data on the Company's proprietary NK- and T-cell TandAbs generated against EGFRvIII.
Poster Number: 231
Title: "EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors"
Date: Thursday, Nov 5, 6:00 p.m. – 7:30 p.m. & Friday, Nov 6, 12:30 p.m. – 2:00 p.m.
The Epidermal Growth Factor Receptor variant III, or EGFRvIII, has been shown to be a highly specific marker for a portion of certain solid tumors including glioblastoma, prostate cancer and head and neck cancer. Based on current research, EGFRvIII is not expressed by healthy tissues, which makes it a unique target for a highly potent cancer immunotherapy such as Affimed's T-cell TandAb®, AFM21.
About NK-Cell TandAbs, T-Cell TandAbs and Trispecific Abs
Affimed develops TandAbs and Trispecific Abs to substantially increase the efficacy, specificity and/or extend the therapeutic window of current therapeutics. TandAbs and Trispecific Abs are a new generation of proprietary, tumor-cell engaging antibodies with a tetravalent architecture characterized by four binding domains. These tetravalent molecules bind to tumor and immune cells with high affinity. Although generation of such complex antibodies is very challenging, Affimed has succeeded in producing them economically and at high quality.
Leveraging this expertise, Affimed has implemented three platform technologies:
- Bispecific TandAbs engaging NK-cells (via CD16A)
- Bispecific TandAbs engaging T-cells (via CD3)
- Trispecific Abs engaging either NK- or T- cells
Affimed's TandAbs have already demonstrated promising signs of therapeutic activity in patients and robust and efficient production processes for these highly stable molecules have been established in mammalian cell systems. Affimed's Trispecific Abs, which target two distinct tumor epitopes and engage T- or NK-cells to lyse the tumor cells that express both targets, are validated preclinically.
About Affimed N.V.
Affimed (ticker:AFMD) is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed's filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
CONTACT: Affimed N.V. Caroline Stewart, Head IR & Communication Phone: +1 347394 6793 E-Mail: IR@affimed.com or firstname.lastname@example.org Media requests: Anca Alexandru or Gretchen Schweitzer MacDougall Biomedical Communications Phone: +49 89 2424 3494 or +49 163 613 3359 E-Mail: email@example.com